

Corporate Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-19 Tel: +91 11 47589500 (30 Lines), 26221811/26418182 E-Mail: info@shivalikrasayan.com

Website: www.shivalikrasayan.com CIN: L24237UR1979PLC005041

Ref: STEX/OUTCOME/2025-26 Date: 14.11.2025

BSE LimitedDepartment of Corporate Services-Listing PJ Towers, Dalal Street
Mumbai- 400001

National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra (E) Mumbai- 400051

Scrip Code- 539148 Symbol- SHIVALIK

Sub. : Outcome of Board Meeting

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter & half year ended on September 30, 2025.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- a) Statement showing the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter & half year ended on September 30, 2025 as **Annexure-A** and
- b) Unaudited Segment-wise Revenue, Results, Assets and Liabilities of the Company, both Standalone and Consolidated, for the quarter & half year ended September 30, 2025; as **Annexure-B** and
- c) Limited Review Report from M/s Rahul Chaudhary & Associates, Chartered Accountant on the Un- Audited Financial Results (Standalone & Consolidated) as Annexure-C

The meeting of the Board of Directors commenced 04:00 p.m. and concluded at 5:30 p.m.

The Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter & half year ended on September 30, 2025, as approved by the Board, will also be available on the Company's website www.shivalikrasayan.com

This is for your information and records.

Thanking You.

Yours faithfully,

For Shivalik Rasayan Limited

Parul Choudhary Company Secretary & Compliance Officer ACS: 34854

	4
M.	
-	
	m

Regd. Office: Village Kolhupani, P.O. Chandanwari, Dehradun- 248007 CIN: L24237UR1979PLC005041 E-mail: cs@shivalikrasayan.com, www.shivalikrasayan.com Shivalik Rasayan Ltd.

_		Un-andi	ted Standalone	nd Concolidator	Discontinu	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	d Einerich B. H. W. W. Shilvailki asayan.com	n.com					
A	PARTI		Sept 2025	na Componinate	u rinanciai Kest	urs for the Qu	arter & Half Y	ear ended on	30th Sept 202	3			
				Standalone	one					All Fi	gures in Rs. La	khs Excepts Ea	All Figures in Rs. Lakhs Excepts Earning Per Shares
		Thr	Three month nerind ended		Tole Van Tr. J. J	Total					Consolidated		
-	Farticulars	30-09-2025	30-06-2025	30-09-2024	30-00-2026	30 00 1014	Year Ended	Thre	Three month period ended	papua	Half Year Ended	r Ended	Year Ended
		IIn-andited	I'm-andited	The condition	6707-60-06	30-02-7074	31-03-2025	30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025
	Income from operations	DAME TO	OII-audited	On-audited	Un-audited	Un-audited	Audited	Unaudited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
	(a) Net Sales/Income from operations	4 777 00					5						
	(b) Other Income	4,007.09	4,626.45	3,769.93	9,293.54	6,928.04	14,922.59	9,384.07	8,930.93	8.244.27	18 315 00	15 707 24	2. 177.31
	Total Revenue	1.36	12.68	6.47	14.24	11.66	206.29	38.84	59.71	35.43	08.55	12,101,01	020.00
ľ	t	4,668.65	4,639.13	3,776.40	9,307.78	6.939.70	15,128,88	9.422.91	8 000 63	0 2 0 2 0	10 412 61	27.66	920.08
	Z Expenses						000000000000000000000000000000000000000	1,144.71	0,770.03	0/7/7/0	18,413.54	15,806.49	32,007.99
	a) Cost of Material Consumed	3,132.23	2,075.91	2.340.05	5 208 14	3 961 65	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	5 220 41	0,000				
_	b) Purchase of Stock-in-Trade	•				20.107.0	26.612.0	1,727.41	4,535.08	5,234.49	6,865.09	9,022.67	17,344.89
_	c) Changes in inventory of Finished Goods	2					•				•	•	
	and Work in Progress	-/34.32	435.88	(448.10)	(318.64)	(328.05)	(700.62)	(636.39)	247.39	(898.44)	(389 00)	(535 70)	/1 303 70
	d) Employees Benefits Expenses	683.21	591.54	634.27	1 274 75	1 080 43	2 314 80	1 556 20	1,000		(and the state of	(11.000)	(1,505,19)
_	e) Finance Cost	122.63	146.43	140 90	260.06	26.000	2,514.09	27,000,1	1,400.57	1,397.70	2,966.86	2,627.41	5,502.18
	1) Depreciation and Amortication European	i c		0000	00.507	67.707	017.70	771.52	261.77	245.00	483.29	436.93	933.37
	the common and control its and its penses	67.187	301.41	204.96	588.70	377.44	870.39	472.96	481.54	465.69	954.50	815.21	1 577 00
	g) Other expenses	918.46	886.42	599.29	1,804.88	976.14	2 393 80	1 921 48	1 640 05	1 224 50	0.00		00:1106
1	Total Expenses	4,389.30	4,437.59	3,471.37	8.826.89	6.329.86	13 776 14	0 075 27	0.575.00	1,554.59	5,570.53	2,478.97	5,613.59
-1	3 Profit/(Loss) before Exceptional Items &	20.020			200-060	201/2010	179//0/14	77.0,00	8,5/5,99	7,779.03	17,451.27	14,845.40	29,667.24
_	_	219.35	201.54	305.03	480.89	609.84	1,352.74	547.64	414.64	500.67	962.27	961.09	2340 75
-	4 Exceptional Items (Commercial Tax Expenses		*			8							2,010,1
	Related to Earlier Year)		•			•	1	•	•		•	8	
	Profit/(Loss) before Extra Ordinary Items	35 075				200							
	•	66.7.7	4C.102	303.03	480.89	609.84	1,352.74	547.64	414.64	500.67	962.27	961.09	2.340.75
i i	6 Tax Expenses												
_	Current Year	76.59	52.92	53.29	129 51	106 55	780 34	144 00	00 001		1		
	MAT Credit Entitlement	-27.78	(17.71)	(53.29)	(45 40)	(106.55)	(100 001)	70.77	109.60	158.54	254.70	295.36	623.29
	Deferred Tax Liability	11.48	44.25	(40 46)	55 73	(25.00)	(102.99)	(27.78)	(17.71)	(53.29)	(42.49)	(106.55)	(102.99)
	Total Tax Expenses	60.29	79 46	(40.46)	130 75	(42.57)	(22.022)	0.11	40.34	(47.20)	40.45	(57.11)	(251.81)
_	7 Net Profit/Loss for the period (5-6)	219.06	122.08	345 50	24115	(42.37)	(33.94)	117.15	132.50	58.05	249.65	131.70	298.49
-	8 Other Comprehensive Income			2000	CITT	14.750	1,386.08	430.49	282.13	442.63	712.62	829.39	2,042.26
	Item that will not be reclassified to Profit &											13	
	Loss		1	i	•	•		i		,			
	Total Comprehensive income Net of Tax	219.06	122.08	345.50	341.15	17 629	1 396 60	430.40	,				
Ľ	Total Comprehensive income for the Period						00.000.61	430.43	CI.707	447.63	712.62	829.39	2.042.26
	(7+8)	219.06	122.08	345.50	341.15	652.41	1,386.68	430.49	282.13	442.63	712.62	829 30	30 040 0
												100100	D. O. T. W. L. O.

Page-02

		1	nded	3006	2707	ted	1.669.62	372.64		787.52	0,0	10.00
70-38rJ		J. Cont.	Year Ended 31-03-2025		1	Audited	y,					
		r Unded	r Enged	30-09-2024		Un-audited	753.31	76.09	000	1/8.01	707	40.4
	Consolidated	Holf Voor Ended	nan rea	30-09-2025		On-audited	491.43	221.18	200	767.37	5	2.12
70-38:1	Cons			30-09-2024	_		400.88	41.75	779 01	10.01	2 58	2.70
		Three month period ended		30-06-2025	IIn-audited	Danma mo	160.05	122.08	787 53	70:10	1 02	
		Three		30-09-2025	Unsudifed		304.59	125.90	787 52		1.93	5
		Year Ended		31-03-2025	Audited		1,386.68	•	787.52		8.80	000
70-		Ended		30-09-2024	Un-audited		652.41	•	778.01		4.19	4 10
r age		Half Year Ended		30-09-2025	Un-audited		341.15		787.52		2.17	717
	lone	pel		30-09-2024	Un-audited		345.50	•	778.01		2.22	2.22
	Standalone	Three month period ended		30-06-2025	Un-audited		122.08	•9	787.52		0.78	0.78
		Three		30-09-2025	Un-audited		219.06	i	787.52		1.39	1.39
			Farticulars			10 Net Profit/ (loss) attribulable to	a) Controlling Interest b) Non Controlling Interest	2	11 Paid-up equity share capital (Rs.5/- per share)	Earning Per Share (Rs.)	(a) Basic	Dimical
_		-	Fa			10 Ne	(g)		11 Pa	12 Ea	(g) {	(a)

1 The Un-audited financial results for the quarter & half year ended 30.09.2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14.11.2025.

The figures are regrouped in previous year also, wherever considered necessary.

The company operates in business segment viz Agro Chemical, Pharma API & Pharma Formulations.

The Earning Per Share has been calculated as per Ind AS-33. Consolidated results of the company includes the results of its Associate i.e., Medicamen Biotech Limited.

Shivalik Rasayan Limited

For & on behalf of Board of Directors

(Rahul Bishnoi)

NAN

Chairman

Place: New Delhi Dated: 14.11.2025



Shivalik Rasayan Ltd.

Sharranse B

Regd. Office: Village Kolhupani, P.O. Chandanwari, Dehradun- 248007

CIN: L24237UR1979PLC005041

E-mail: cs@shivalikrasayan.com, www.shivalikrasayan.com Un-audited Standalone & Consolidated segment wise revenue, results, assets and liabilities for the Quarter & Year Ended 30th Sept' 2025

S	Sl. No Particulare												
				Standalone	one					Consc	Consolidated		
		Three n	Three months period ended	nded	Half Year	Year	Year Ended	Three	Three month period ended	ended	Half Year	Vear	Van Fridad
		30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025	30-09-2025	30-06-2025	20 00 201	-000 00 00		Year Emgen
1	1	Un-audited	Un-audited	Un-audited	Iln-andited	I'm-andited	4 4 3		207-00-00	20-03-5054	30-09-2025	30-09-2024	31-03-2025
	1 Segment revenue				namma ma	On-auniten	Audited	Un-audited	Un-audited	Un-andited	Un-audited	Un-audited	Andited
	A. Agrochemicals	4 437 47	4 433 88	3 601 00	20.00			000000000000000000000000000000000000000					
	B. Active Pharma Ingredient (API)	145 58	102 53	167.06	6,6/1.35	0,578.21	14,172.24	4,437.47	4,433.88	3,601.98	8,871.35	6,578.21	14,172,24
	C. Pharma Formulation		76.76	101.93	338.10	349.83	640.35	145.58	192.52	167.95	338.10	349.83	640.35
	D. Unallocated other operating revenue	84 04	. 900	ı		(•	4,716.98	4,304.48	4,474.34	9,021.46	8,779.20	16.254.72
	Total Revenue	4.667.09	4 676 45	2 760 03	84.10		110.00	84.04	90.0	•	84.10	,	•
	2 Segment results	Control of the contro	Or comple	2,,07.73	7,473.34	6,928.04	14,922.59	9,384.07	8,930.93	8,244.27	18,315.00	15,707.24	31,067,31
-	A. Agrochemicals	697.25	643.92	720.30	1.341.17	1.378.66	2 865 41	36 209	643.00	00000			
	B. Active Pharma Ingredient (API)	(295.28)	(295.95)	(274.38)	(591.23)	(506.58)	(894 92)	(205 28)	705.92	720.30	1,341.17	1,378.66	2,865.41
_	C. Pharma Formulation	•	•	i	•	,	(=	367 10	220.93)	(274.58)	(55.123)	(506.58)	(894.92)
_	Sub Total	401.97	347.98	445.92	749 94	877 08	1 070 40	307.18	328.44	299.73	695.62	525.94	1,303.61
	Less:Finance costs	122.63	146 43	140 90	269.06	267.75	1,9/0.49	769.15	676.42	745.65	1,445.56	1,398.02	3,274.10
	Less: Unallocable expenditure net of			00.041	203.00	707.73	917.70	221.52	261.77	244.98	483.30	436.92	933.37
	unallocable income	•	ŗ		5		ī		•	1	,		
	Profit before exceptional items and tax	279.35	201.54	305.03	480 80	600 04	1 350 51	7,000					
	Exceptional Items	•	,		Corner.	10.000	1,335.74	547.64	414.64	200.67	962.27	961.09	2,340.73
	Profit/(Loss) before tax	279.35	201 54	305.03	400 00	. 000	,				•	1	
	Less: Tax Expenses	60.29	70.46	303.03	490.89	609.84	1,352.74	547.64	414.64	200.67	962.27	961.09	2,340.73
	Net Profit/(Loss) for the period/year	219.05	132.00	(40.40)	139.75	(42.57)	(33.94)	117.15	132.50	58.05	249.65	131.70	298.49
100	3 Segment assets	412,00	142.00	345.50	341.15	652.41	1,386.68	430.49	282.13	442.63	712.62	829.39	2,042.24
	A. Agrochemicals	33,227.93	32,683,30	30.843.31	33 227 93	30 843 31	31 056 73	22 227 03	00,000,000				
	B. Active Pharma Ingredient (API)	10,960.10	11,178.82	11.078.07	10 960 10	11 078 07	11 385 04	10,060,10	11 178 82	30,843.31	33,227.93	30,843.31	31,956.23
	C. Pharma Formulation	•			2	2000	10.000,11	10,900.10	11,178.82	11,078.07	10,960.10	11,078.07	11,385.04
	D. Unallocated							33,097.08	33,097.08	29,452.24	33,097.08	29,452.24	29,407.46
4	Total	44.188.04	43.862.11	41.921 38	44 188 04	41 021 30	12 244 24		1		э	•	1
	Segment liabilities				10000161	41,741.30	43,341.27	71.682,17	76,959.19	71,373.62	77,285.12	71,373.62	72,748.73
	A. Agrochemicals	6,746.78	16,089.49	11.043.55	6.746.78	11 043 55	10 070 04	677670	07 000 31				
_	B. Active Pharma Ingredient (API)	604.20	611.96	323.52	604.20	323.52	415.68	604.70	10,089.49	11,043.55	6,746.78	11,043.55	10,979.94
_	C. Pharma Formulation	•	1		1	-	2	02.400	011.90	523.52	604.20	323.52	415.68
	D. Unallocated	Ċ	٠		e- a			3,650.74	3,650.74	8,905.11	3,650.74	8,905.11	5,046.06
	Total	7.350.97	16.701.45	11 367 07	7 350 07	11 367 07	11 305 62						•
		· and ·	TABLETA		16,000,1	1.70/.07	2	11 001 71	20 352 10	30 323 10	*** 000 **		

Place: New Delhi

11,001.71

20,272,18

20,352,19

11,001.71

11,395.62

11,367.07

Dated : 14.11.2025

属

SHIVALIK RASAYAN LIMITED

Regd. Office: Village Kolhupani, P.O. Chandanwari, Dehradun- 248007

CIN: L24237UR1979PLC005041

STATEMENT OF ASSETS & LIABILITIES

г	DITTEMENT	Stan	dalone	Conso	lidated
г	PARTICULARS	30.09.2025	31.03.2025	30.09,2025	31.03.2025
ı		(Amount in Rs.	(Amount in Rs.		Date of the second second
ı		Lakhs)	100	(Amount in Rs.	(Amount in Rs.
I.	ASSETS	Lakiis)	Lakhs)	Lakhs)	Lakhs)
-	1. Non-current assets		n		- 5
ı	(a) Property Plant & Equipment	25,141.07	24.062.02	22 620 00	
ı	(b) Other Intangible Assets	23,141.07	24,953.93	33,638.72	33,590.15
	(c) Capital work-in-progress	1 -	-	65.87	74.23
ı	(d) Investment Property	_	-	-	
ı	(e) Goodwill	-	-		-
				-	-
	(f) Intangible assets under development		-	-	1
	(g) Biological Assets other than bearer plants	-	-		
	(h) Financial Assets		. 1		
	(i) Investments	8,109.13	7,446.63	-	-
	(ii) Trade Receivables		-	-	-
	(iii) Loans and Advances	132.76	134.76	528.00	534.22
	(iv) Others (to be specified)		=	- 1	
	(i) Deferred Tax Assets (net)	317.02	372.75	613.20	655,75
	(j) Other non-current assets	4,115.44	2,968.89	8,423.93	7,111.10
	Total non-current assets	37,815.42	35,876.97	43,269,72	41,965.46
	10 to			, , , , , , , , , , , , , , , , , , , ,	,
	2. Current assets	1 1			
	(a) Inventories	6,172.30	5,556.30	13,049.13	11,770.04
	(b) Financial Assets	.,	-,	15,045.15	11,770.04
	(i) Investments			_0	
	(ii) Trade Receivables	3,474.41	2,721.62	11,231.46	9,611.59
	(iii) Cash and cash equivalents	315.94	2,421.01	4,683.86	
	(iv) Bank balances other than (iii) above	/ 515.54	2,421.01	4,003.00	2,796.95
	(v) Loans & Advance	102,67	170,47	260.40	474.00
	(vi) Others (to be specified)	102.07	170.47	369.42	474.08
	(c) Current Tax Assets (Net)			,	-
- 1	(d) Other Current Assets	4 722 46	4 414.00	-	
- 1	Total current-assets	4,733.46	4,414.28	7,806.27	6,810.96
	Total cultent-assets	14,798.77	15,283.68	37,140.15	31,463.62
- 1	TOTAL ASSETS	52,614.19	51,160.65	80,409,87	73,429.07
			,	00,103,07	13,427.01
Π.	EQUITY AND LIABILITIES				
	1. Equity	1			
	(a) Equity Share Capital	787.52	787.52	787.52	787.52
	(b) Other Equity	39,239.89	38,977.51	57,865.68	52,836.18
- 1	(c) Share/Warrant Application Money Received		- 1		-
- 1	(d) Minority Interest	-	-		
- 1	Total Equity	40,027.41	39,765.03	58,653.20	53,623.70
- 1					,
	Liabilities		1		
- 1	2. Non-current liabilities				
	(a) Financial Liabilities				
	(i) Borrowings	1,767.09	1,276,54	2,128.83	1,649.98
	(ii) Trade payables	1,707.09	1,270.54	2,120.03	1,049.98
	(iii) Other financial liabilities		1921	- 1	9
	(b) Provisions	152.72	115.55	402.12	225.00
	(c) Deferred Tax Liabilities (net)	132.72	113.33	402.12	335.99
1	(d) Other non-current liabilities		-	0.12	(0.31)
١,	Total non-current libilities	1 010 01	1 202 00	2 724 05	
	- Common current institutes	1,919.81	1,392.09	2,531.07	1,985.67
	3. Current Liabilities			1	
	(a) Short-term borrowings	4,406.41	4,786.46	7,909.54	7,738.33
	(a) Financial Liabilities	.,	.,,,,,,,,,,,	1,505.54	1,130.33
-	(i) Borrowings		_		
	(ii) Trade payables	5,123.20	2,365.82	0.441.52	6 (20.00
1	(iii) Other financial liabilities	5,125.20	2,303.62	9,441.52	6,630.99
1	(b) Other Current liabilities	460.69	2 242 41	(27.20	2 100 05
	(c) Provisions	257.82	2,342.41	627.39	2,489.22
	(d) Current tax liabilities (Net)		219.50	339.16	339.39
1	(d) Current tax habilities (Net)	418.86	289.34	907.99	621,77
11	our current indinutes	10,666.98	10,003.53	19,225.61	17,819.70
1	TOTAL EQUITY & LIBILITIES	52,614.19	51,160.65	80,409.87	73,429.07
_		,022	/ KA	0 00,407.07	13,447.0/

For & on behalf of Board of Directors Shivalik Rasayan Limited

> (Rahul Bishnoi) Chairman

Place: New Delhi Dated: 14.11.2025



SHIVALIK RASAYAN LIMITED

Regd. Office: Village Kolhupani, P.O. Chandanwari, Dehradun- 248007

CIN: L24237UR1979PLC005041

CASH FLOW STATEMENT FOR THE PERIOD 01.04.2025 TO 30.09.2025

PARTICULARS		STAND	ALONE		Amount in Rs. Lakh
		30.09.2025	31.03.2025	30.09.2025	31.03.2025
A. Cash flow from Operat					7110012020
	from continuing operations	341.15	1,386.69	712.63	2,042.2
	reconcile profit before tax to net cash flows		12 100		
Provision for Taxation		84.02	186.35	209.21	550.2
Adjustments for Deffered	Tax	55.73	(220.29)		
Financial Charges		269.06	617.76	483.29	
Loss/(Profit) on sale of Fi	xed Assets	Ε.	-		_
Interest Income		(14.02)	(206.28)	(79.46	(257.0
Depreciation	, a s	588.70	870.39	954.50	
Operating Profit before	Working Capital Changes	1,324.64	2,634.62	2,320.62	4,578.4
Movements in working ca		1986 1790 6 (1990 - 1991	40-12-00-14-00-00-00-00-00-00-00-00-00-00-00-00-00		1,07011
Increase/(decrease) trade		2,757.38	1,040.03	2,810.54	1,410.3
Increase/(decrease) in long	g term provisions	37.17	53.53	66.13	98.3
Increase/(decrease) in sho		273.79	(98.54)		(508.7
Increase/(decrease) in other		(1,881.72)	(1,075.50)		
Decrease/(Increase) in trace	le receivables	(752.79)	426.64	(1,619.88)	
Decrease/(Increase) in inv		(616.00)	(1,311.13)		
Decrease/(Increase) in Ion		2.00	248.76	(268.78)	
Decrease/(Increase) in sho	rt term loans and advances	67.80	(51.90)		33.4
Decrease/(Increase) in other		(319.18)	(358.58)		
Decrease/(Increase) in other	er non current assets	(1,146.55)	(1,472.29)	(,	
Direct taxes paid		(190.00)	(140.00)	(485.00)	
Net Cash Flow from Ope	rating Activities (A)	(443.46)	(104.36)		
	6		, ,	(-7	(>2012
B. Cash Flow from Investin		81 8		+	
Addition to Fixed Assets in		(775.84)	(2,073.51)	(993.34)	(2,263.9)
Purchase of non-current in	vestments	(662.50)	(103.93)	(662.50)	
Interest Received		14.02	206.28	79.46	257.0
Adjustment toward depreca		-	•	-	-
Net Cash Flow from Inve	sting Activities (B)	(1,424.31)	(1,971.16)	(1,576.37)	(2,110.8
C. Cash Flow from Financia	a Activities		ja e	·	3
Proceeds from issuance of		(0.00)	9.50	04.00	
Proceeds from Securities P.		(0.00)		84.82	9.5
Proceeds from Share Warra		- 1	1,350.90	4,410.72	1,350.9
Troopeds from ondio want		- 1	-	861.25	
Capital Reserve					52.1
Share /Warrants application	Money Received	-	_		32.1
Net proceeds of long term b	orrowings	490.55	(994.70)	478.86	(746.8)
Net proceeds of short term	porrowings	(380.05)	2,531.21	174.44	2,526.9
Financial Charges		(269.06)	(617.76)	(483.29)	0.5
Income tax provision revers	e for earlier year	(203.00)	(017:70)	(403.29)	(933.37
Dividend paid on equity sha	ares	(78.75)	(77.80)	(70.75)	(204.0
Preferational issue Expendi		(10.13)	(77.00)	(78.75) (300.44)	(204.95
Net Cash Flow from Final		(237.31)	2,201.35	5,147.61	2,054.29
ET INCREASE//DECDEAG	E) IN CASH & CASH EQUIVALENTS (-			#I
ET INCREASE/(DECREAS	E) IN CASH & CASH EQUIVALENTS ((2,105.08)	125.83	1,886.92	(976.80
ASH & CASH EQUIVALE	TTS AT THE START OF THE YEAR	2,421.02	2,295.19	2,796.95	3,773.75
	ı				

Place: New Delhi Dated: 14.11.2025 For & on behalf of Board of Directors

Shivalik Rasayan Limited

(Rahul Bishnoi) Chairman



RAHUL CHAUDHARY & ASSOCIATES

Chartered Accountants

LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY AND YEAR-TO-DATE STANDALONE FINANCIAL RESULTS OF SHIVALIK RASAYAN LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS)

REGULATIONS, 2015

To

The Board of Directors, Shivalik Rasayan Ltd. Village Kolhupani, P.O. Chandanwari, Dehradun-248007

We have reviewed the accompanying statement of unaudited financial results of M/s Shivalik Rasayan Limited having its corporate office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter and half year ended September 30, 2025 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS - 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 read with Regulation 63(2) of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Rahul Chaudhary & Associates

Rahul Chaudhary M. No. 542837

Firm Reg. No. 033971N

UDIN: 25542837BMOQXQ2412

Place: Faridabad Date: 14.11.2025

CA

RAHUL CHAUDHARY & ASSOCIATES

Chartered Accountants

LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY AND YEAR-TO-DATE CONSOLIDATED FINANCIAL RESULTS OF SHIVALIK RASAYAN LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To

The Board of Directors, Shivalik Rasayan Ltd. Village Kolhupani, P.O. Chandanwari, Dehradun-248007

- 1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of SHIVALIK RASAYAN LIMITED ("the Parent") and its associate (the Parent and its associate together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its associate for the quarter and half year ended September 30, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

- 5. The Statement includes the results of the Medicamen Biotech Limited (the "Associate" Company)
- 6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 and 7(ii) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid id Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.



RAHUL CHAUDHARY & ASSOCIATES

Chartered Accountants

7. The Statements includes the Group's share of net profit after tax of Rs. 211.43 Lakhs for the quarter ended on September 30, 2025, as considered in the consolidated unaudited financial results, in respect of an associate, based on their interim financial information which has not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

Our conclusion on the Statement is not modified in respect of the above matter.

Chartered

Accountant

For M/s Rahul Chaudhary & Associates

Rahul Chaudhary M. No. 542837

Firm Reg. No. 033971N UDIN: 25542837BMOQXP4157

Place: Faridabad Date: 14.11.2025

> Reg. Office: - T4-204, Zion Lake View Apartment, Sector-48, NIT, Faridabad-121001 Email ID: - ca.chaudhary19@gmail.com, Contact No: - 9811372158